Title:
METHODS OF ADMINISTERING ELAGOLIX
Document Type and Number:
WIPO Patent Application WO/2022/165097
Kind Code:
A8
Abstract:
The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis. In particular, the present disclosure describes methods for treating such gynecological disorders, where the methods involve administration of elagolix and may further involve co-administration of a CYP2B6 substrate (e.g., bupropion) or a CYP2C19 substrate (e.g., omeprazole) or a CYP3A4 substrate (e.g., ethinyl estradiol and/or levonorgestrel).
Inventors:
SHEBLEY MOHAMAD (US)
CHENG LING (US)
MANCHANDANI POOJA (US)
CHENG LING (US)
MANCHANDANI POOJA (US)
Application Number:
PCT/US2022/014195
Publication Date:
February 29, 2024
Filing Date:
January 28, 2022
Export Citation:
Assignee:
ABBVIE INC (US)
International Classes:
A61K31/513; A61K31/567; A61P5/24; A61P15/00
Attorney, Agent or Firm:
SRIVASTAVA, Sonali et al. (US)
Download PDF: